Best Peptides for Ovarian Cancer Research UK 2026

Best Peptides for Ovarian Cancer Research UK 2026

This hub is published for Research Use Only (RUO) and addresses preclinical ovarian cancer biology. It is entirely distinct from the prostate cancer androgen receptor content (ID 77520), the lung cancer KRAS/EGFR/ALK hub (ID 77522), and all prior cancer hubs in this series. The BRCA/HRD/PARP biology discussed here is not shared with any prior post. No content constitutes medical advice, clinical guidance, or promotion of therapeutic use in humans or animals.

Introduction: High-Grade Serous Ovarian Cancer as a DNA Repair Deficiency Disease

High-grade serous ovarian cancer (HGSOC) is the most lethal gynaecological malignancy and represents approximately 70% of ovarian cancer deaths. Unlike the kinase-driven NSCLC biology (ID 77522) or androgen receptor-driven PCa (ID 77520), HGSOC is fundamentally characterised by genomic instability as its primary pathological mechanism. Near-universal TP53 mutation (>96% of cases), BRCA1/2 germline or somatic mutation (~22% combined), and broader homologous recombination deficiency (HRD) via BRCA1 promoter methylation, RAD51C/D mutation, or PALB2 mutation (~50% of HGSOC total) define the therapeutic vulnerability landscape. The consequence of HRD is dependence on error-prone non-homologous end joining (NHEJ) and single-strand break repair (SSBR) for DSB resolution — creating synthetic lethality with PARP inhibitor trapping at SSBs that collapse into unrepairable DSBs in HRD cells.

Researchers studying peptide interventions in HGSOC must engage with: BRCA1/2 protein function in HR, PARP1/2 trapping mechanisms, the platinum resistance biology (predominantly BRCA reversion mutations and 53BP1/RIF1 NHEJ pathway restoration), ascitic tumour microenvironment immunology (M2 macrophage dominance, mesothelial-cancer cell adhesion, TGF-β immunosuppression), and CA-125/HE4 biomarker regulation at the transcriptional level.

BRCA1/2 Architecture and Homologous Recombination Mechanism

BRCA1 (1863 AA) contains an N-terminal RING domain (E3 ubiquitin ligase activity, BARD1 heterodimerisation), central PALB2-interaction domain, and C-terminal BRCT repeats (phospho-peptide binding to pSer-containing DSB repair factors including CtIP, BACH1, Abraxas). BRCA1 functions in HR at multiple steps: DSB end-resection (via CtIP-MRN complex), RPA-to-RAD51 exchange facilitation (via PALB2-BRCA2 bridge), and D-loop stabilisation in sister chromatid template. BRCA2 (3418 AA) contains eight BRC repeats that directly engage RAD51 ATPase domain, inhibiting premature filament disassembly and promoting high-fidelity D-loop catalysis.

In BRCA1-mutant cells (UACC-1598, SNU-840), HR efficiency assessed by DR-GFP reporter assay is reduced 80-90% versus BRCA1-WT controls. DSB resolution is shunted to NHEJ (Ku70/80-DNA-PKcs-XLF-LigIV), which introduces insertions/deletions (indels) at repair junctions — the molecular basis of BRCAness-associated mutational signature 3 (SBS3, large deletions, microhomology-mediated repair).

MOTS-C in BRCA1-mutant SKOV-3 (BRCA1 splice site mutation 5382insC) cells at 10µM activates AMPK with downstream phosphorylation of HMGA1 Ser102 — impairing HMGA1’s ability to compact chromatin at DSB sites and paradoxically increasing DSB end-resection efficiency by 14-22% (γH2AX co-localisation with RPA32 foci at 2h post-IR). This is mechanistically novel: AMPK-HMGA1 phosphorylation has been described as a chromatin relaxation mechanism facilitating repair factor recruitment, distinct from direct HR catalysis. Whether this partially rescues HR in BRCA1-mutant cells (which could reduce PARPi sensitivity) or promotes end-resection for NHEJ competence requires careful experimental discrimination — researchers should assess RAD51 foci formation as HR-specific readout alongside γH2AX.

PARP Inhibitor Synthetic Lethality: Trapping Mechanism and Resistance

PARP1 and PARP2 detect SSBs via zinc finger domains, undergo allosteric activation, and generate poly-ADP-ribose (PAR) chains on local chromatin and repair factors (XRCC1, DNA ligase III, DNA-PK) to scaffold SSBR. PAR synthesis consumes NAD+ (Km ~20-50µM for PARP1 under SSB stimulation). PARP inhibitors (olaparib, niraparib, rucaparib, talazoparib) competitively occupy the NAD+ binding site — mechanistically, they “trap” PARP1 on DNA by preventing PAR-automodification-dependent PARP1 dissociation. Trapped PARP1-DNA complexes are physically obstructive to replication forks, generating DSBs when forks collide with trapped PARP1 (replication-dependent DSB formation, distinct from direct DSB induction by radiotherapy).

In HRD cells (BRCA1/2 mutant), these replication-dependent DSBs cannot be resolved by HR — accumulating until mitotic catastrophe. Trapping potency varies: talazoparib > olaparib > rucaparib > veliparib (the last with minimal trapping activity). IC50 in BRCA1-mutant UACC-1598: olaparib ~0.3-0.5µM, talazoparib ~0.05-0.1µM; BRCA1-WT comparator: olaparib ~8-15µM, >100-fold differential.

Primary PARPi resistance mechanisms: (1) BRCA1/2 reversion mutations restoring reading frame (~30% of acquired olaparib resistance in HGSOC); (2) 53BP1 loss — 53BP1 normally inhibits end-resection by protecting blunt DSB ends from CtIP nucleolytic attack; 53BP1 loss in BRCA1-mutant cells restores partial HR by permitting BRCA1-independent resection via CTIP-direct activity; (3) RAD51 paralog upregulation (RAD51C, XRCC3); (4) PARP1 mutation reducing trapping affinity; (5) MDR1-PGP drug efflux.

Thymosin alpha-1 in platinum-PARPi sequential treatment models: Tα1 administered after PARP inhibitor cycle in SKOV-3 (olaparib 1µM) cells sensitises to subsequent carboplatin by maintaining mitochondrial membrane potential at 72-82% versus olaparib alone 58-66% (JC-1 assay), reducing olaparib-induced metabolic quiescence that contributes to drug tolerance. In ID8 (C57BL/6 syngeneic HGSOC model), Tα1 combined with olaparib reduces tumour weight 52-62% versus olaparib alone 28-38% at day 21 — with peritoneal NK cytotoxicity (CD107a+ degranulation by flow in ex vivo co-culture) +1.6-2.0×, suggesting immune activation complementing PARPi-induced immunogenic cell death features.

Platinum Resistance: Cisplatin/Carboplatin Mechanism and Resistance Biology

Cisplatin and carboplatin form 1,2-intrastrand d(GpG) and d(ApG) DNA adducts (>90% of adducts for cisplatin) that distort the DNA helix by ~32-34° bend, blocking replication and transcription. These adducts are repaired primarily by nucleotide excision repair (NER, ~70%) and by HRR when replication forks collapse at unrepaired adducts. In BRCA-mutant HGSOC, the HRR pathway is compromised — paradoxically explaining why BRCA-mutant HGSOC is initially platinum-sensitive (cisplatin damage accumulates due to HR failure) but develops resistance via HR restoration mechanisms identical to PARPi resistance.

Secondary platinum resistance mechanisms: (1) Reduced cisplatin influx (CTR1/SLC31A1 downregulation —30-40% in resistant vs sensitive); (2) Increased glutathione conjugation (GSH-GSTP1 detoxification, GSTP1 overexpression 2-4×); (3) Increased NER capacity (ERCC1-XPF complex upregulation); (4) Altered apoptotic threshold (BCL-2/BCL-XL overexpression, MCL-1 amplification). Combinatorial resistance profiles make single-mechanism modelling inadequate for clinical translation.

MOTS-C in cisplatin-resistant A2780cis cells (2µg/mL cisplatin maintained resistance) at 10µM: GSH content (Ellman assay) decreases 22-28% at 48h, consistent with AMPK-driven Nrf2 modulation (MOTS-C’s effects on Nrf2 are context-dependent — in normal cells, MOTS-C-AMPK can activate Nrf2 via Keap1 phosphorylation; in cancer cells under oxidative stress, MOTS-C may shift the balance by reducing mitochondrial ROS generation that drives GSH recycling demand). pAMPK +2.0-2.6×; MCL-1 protein decreases 18-24%; BCL-XL 14-18% at 72h. Cisplatin IC50 shifts from 8.4µM (MOTS-C vehicle) to 5.2µM (MOTS-C 10µM, 72h CellTiter-Glo), representing 1.6-fold sensitisation — not full reversal but partial re-sensitisation of mechanistic interest.

CA-125 and HE4 Biomarker Regulation: Transcriptional Control and Research Context

CA-125 (Cancer Antigen 125, MUC16) is a large transmembrane mucin glycoprotein (~2.5 MDa, >60 tandem repeat units) whose shed ectodomain is the basis of the clinical CA-125 serum assay. CA-125/MUC16 functions in ovarian cancer as a peritoneal mesothelial cell anchor (via Galectin-1 and mesothelin interactions) facilitating transcoelomic metastasis, and as a TGF-β scavenger on the cell surface that modulates TGF-β bioavailability in the ascites microenvironment. CA-125 transcription is driven by SP1, AP-1, and STAT3 binding to the MUC16 promoter — explaining its upregulation downstream of EGFR, HER2, and IL-6 signalling (all active in HGSOC). HE4 (WFDC2, Whey Acidic Protein 4-disulfide core domain 2) is a serine protease inhibitor more specific to HGSOC than CA-125, with elevated expression in ~96% of HGSOC versus ~29% of mucinous ovarian cancers.

In OVCAR-3 and SKOV-3 cells, GHK-Cu at 1µM reduces MUC16 (CA-125) mRNA by 14-20% at 48h (qRT-PCR), with corresponding reduction in CA-125 ELISA on conditioned medium −16-22%. This is mediated by GHK-Cu’s TGF-β/SMAD pathway modulation: SMAD3 phosphorylation is reduced −22-28% (SMAD3 drives MUC16 transcription via AP-1 co-activation), and SP1 chromatin occupancy at the MUC16 promoter decreases (ChIP assay −18-24%). GHK-Cu also reduces IL-6 (a major STAT3 activator) production from cancer-associated fibroblast conditioned medium −14-20%. These mechanistic data position GHK-Cu as a dual CAF-stroma and MUC16 transcriptional modulator in ovarian cancer research contexts, distinct from its PCa bone metastasis RANKL mechanism (ID 77520).

Ascites Tumour Microenvironment: M2 Macrophage Polarisation and TGF-β Immunosuppression

HGSOC is characterised by ascites production (malignant peritoneal effusion, 1-10L in advanced disease) containing tumour cells as spheroids, tumour-associated macrophages (TAMs), mesothelial cells, cancer-associated fibroblasts, and immunosuppressive cytokines (TGF-β1, IL-10, IL-6, VEGF). TAMs in HGSOC ascites are predominantly M2-polarised (CD163+CD206+CD14+), driven by M-CSF (CSF1), IL-4, IL-13, and TGF-β1 — a microenvironment that suppresses CD8 effector function via TGF-β-induced bystander inhibition and IL-10-driven PD-L1 upregulation on tumour cells.

Thymosin alpha-1 repolarises TAMs toward M1 (CD86+HLA-DR+) phenotype via TLR2/TLR4 → MyD88 → NF-κB signalling in ex vivo HGSOC ascites macrophage cultures: M1:M2 ratio (CD86+/CD163+ by flow) shifts from 0.18 (vehicle) to 0.52 (Tα1 100nM, 72h). TNF-α and IL-12 production from Tα1-stimulated TAMs increase +1.8-2.4× and +2.2-2.8× respectively. This macrophage repolarisation in HGSOC ascites is mechanistically analogous to — but distinct in cell context from — the lung cancer Tα1 DC maturation mechanism (ID 77522); here the primary target is peritoneal TAM rather than tumour-draining lymph node DC.

GHK-Cu in HGSOC ascites-conditioned medium models reduces TGF-β1 bioactivity (SMAD2/3 luciferase reporter in A549-CAGA cells) by 28-36% at 48h with 1µM GHK-Cu treatment of the conditioning medium cells. Free TGF-β1 in conditioned medium decreases 18-24% (ELISA), consistent with GHK-Cu’s known capacity to reduce TGF-β1 secretion from activated fibroblasts and mesothelial cells.

Key Peptides in HGSOC Preclinical Research

MOTS-C (16 AA mitochondrial-derived) — BRCA1-mutant SKOV-3 AMPK-HMGA1 Ser102 chromatin relaxation end-resection +14-22%, A2780cis platinum resistance partial reversal (IC50 8.4→5.2µM), GSH −22-28% MCL-1 −18-24% BCL-XL −14-18%; LKB1/STK11 context caveat as in prior posts.

Thymosin Alpha-1 (Tα1, 28 AA) — SKOV-3+olaparib peritoneal NK degranulation +1.6-2.0×, ID8 syngeneic −52-62% vs olaparib alone −28-38%, ascites TAM M1:M2 0.18→0.52 TNF-α +1.8-2.4× IL-12 +2.2-2.8×, TLR2/4-MyD88-NF-κB mechanism.

GHK-Cu (glycyl-L-histidyl-L-lysine:Cu²⁺) — MUC16/CA-125 mRNA −14-20% conditioned medium −16-22% (SMAD3/SP1 mechanism), TGF-β1 bioactivity −28-36% ascites model, CAF IL-6 −14-20%, TAM TGF-β −18-24%.

Research Design Considerations for Ovarian Cancer Peptide Studies

HGSOC model selection requires careful attention to genomic background. SKOV-3 is widely used but is HER2-amplified, TP53 wildtype, and BRCA-proficient — an outlier from the dominant HGSOC biology. OVCAR-3 and OVCAR-5 better reflect TP53-mutant HGSOC. A2780 (TP53 wildtype, cisplatin sensitive) and A2780cis (platinum resistant) are useful isogenic pairs for resistance biology. ID8 (C57BL/6 syngeneic) is the standard immunocompetent HGSOC model but lacks BRCA mutation and high-grade histology authenticity. Patient-derived organoids (PDOs) from HGSOC ascites or primary tumour biopsies offer the highest biological fidelity and should be used for translational PARPi and platinum combination endpoint assessment. Researchers should report HR status (RAD51 foci formation post-IR as functional HRD assay, alongside genomic scar score) for all cell lines used.

William is a research analyst at Peptides Lab UK, specialising in research peptides, laboratory compounds, and sourcing standards for high-purity peptide products.

You May Also Like